The Presidents of Ruanda and Senegal, EU Commission President Ursula von der Leyen and EIB President Werner Hoyer met BioNTech-Founder Uğur Şahin to discuss the development of vaccine production for Africa.
BioNTech affirmed its intention to manufacture any vaccines arising from its development of vaccine candidates to fight malaria and tuberculosis on the African continent.
Today, President Paul Kagame of Rwanda, President Macky Sall of Senegal, President Ursula von der Leyen of the European Commission and EIB President Werner Hoyer met Uğur Şahin, CEO and co-founder of BioNTech, at the Barenboim-Said-Akademie in Berlin to discuss the development of sustainable vaccine production for Africa.
The meeting, which was convened by the kENUP Foundation on behalf of BioNTech, took place on the margins of the G20 Compact with Africa Summit hosted by German Chancellor Angela Merkel. Also in attendance were Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention (Africa CDC), Dr Matshidiso Moeti, WHO Africa Regional Director, and Werner Hoyer, President of the European Investment Bank (EIB).
The meeting resulted in a joint communiqué affirming BioNTech’s intention to manufacture any vaccines arising from the development of its malaria and tuberculosis vaccine candidates in Africa. The company has started evaluating manufacturing options in Rwanda and Senegal following the guidance of the African Union. These options will be co-located with the WHO’s upcoming vaccine hubs. In the interim, it should be possible to develop BioNTech’s COVID-19 vaccine in local facilities for distribution in Africa. Other vaccine and pharmaceutical production facilities may also be established in these hubs to ensure a sustainable commercial and scientific ecosystem.
BioNTech’s malaria project is part of the eradicateMalaria initiative, led by the kENUP Foundation, to accelerate the eradication of malaria. The kENUP Foundation is a non-profit public benefit foundation supporting research-based innovation in the wider health industries for societal benefit. Following the guidance of the WHO and the eradicateMalaria Scientific Advisory Board, further projects by various companies may be considered under the eradicateMalaria scheme.
Collaboration Africa CDC under the Partnership for African Vaccine Manufacturing programme will ensure that the enabling factors such as regulatory alignment, policy transfer and country coordination are in place to get the vaccines from factories into the arms of people in Africa, and beyond.
“We would like to thank all participants for today’s discussion, their support and the trust they put in us. Our goal is the development of vaccines in Africa and the set-up of sustainable vaccine production capabilities to jointly improve the quality of medical care,” said Ugur Sahin, CEO and co-founder of BioNTech. “We are committed to investing in cutting-edge research and innovation to support vaccine development, the establishment of manufacturing facilities, and the transfer of manufacturing expertise to production sites on the African continent.”
Ursula von der Leyen, President of the European Commission: “This cooperation is an important moment for Africa and a great step towards vaccine equity. mRNA vaccines are cutting-edge technology. And it’s a powerful sign that we all join forces to make it possible to produce them in Africa. Team Europe is investing at least €1 billion to facilitate manufacturing and access to vaccines in Africa. And we are proud to be a partner in this endeavour.”
Werner Hoyer, President of the European Investment Bank: “Scaling up local vaccine production is crucial to beating COVID and strengthening resilience to future pandemics. Since the start of the COVID pandemic, the European Investment Bank has worked closely with African and international partners to support private and public investment to improve health and ensure that businesses can invest. We welcome this new initiative and stand ready to provide technical experience and financial backing in the coming months.”
John Nkengasong, Director of Africa CDC: “Africa CDC, in its role leading the AU Partnership for African Vaccine Manufacturing (PAVM), welcomes this demonstration of the commitment of kENUP, BioNTech and the European Union to expanding vaccine manufacturing capacity on the African continent. The PAVM aims to increase vaccine manufacturing across Africa from 1% to 60% by 2040, prioritising endemic and outbreak-prone diseases, and also focusing on conditions that disproportionately affect our continent such as HIV and malaria. The ambition is to leverage new technology in support of a sustainable manufacturing industry on the continent. This initiative joins others across the continent in pushing forward this vision. We encourage other partners, manufacturers, financiers and others to join us to make this ambition a reality.”
Paul Kagame, President of the Republic of Rwanda: “"We are on the path to bringing vaccine manufacturing to Africa sooner rather than later. The technology to make it possible is available. Most importantly, there is a sense of urgency. Rwanda looks forward to working on this initiative in close collaboration with BioNTech and other partners in Africa and beyond."
Macky Sall, President of the Republic of Senegal: “This initiative is a very good step toward self-reliance in vaccines including in covid vaccine launched with the MADIBA – Institut Pasteur de Dakar project. Supporting such initiatives to materialize quickly in Africa, would contribute to boosting covid vaccine access and to building a sustainable health security for a stronger and more equitable economic recovery globally.”
Reeta Roy, President & CEO of Mastercard Foundation: “The Africa Union has set a bold goal: to ensure that 60 percent of Africa’s vaccine demand will be met through production in Africa by 2040. This collaboration between the governments of Rwanda and Senegal and BioNTech is a positive step towards that vision. Manufacturing vaccines in Africa will increase health security and create jobs for young people in the future. As part of our Saving Lives and Livelihoods initiative, the Mastercard Foundation will continue to support the efforts of the African Union, Africa CDC, and other leaders to develop the talent across Africa for vaccine manufacturing.”
Holm Keller, Executive Chairman of kENUP Foundation: “Vaccine Equity cannot be achieved without Africa joining the global manufacturing platforms for essential biologicals. Today's move by the Republic of Rwanda, the Republic of Senegal and BioNTech is an important step for achieving this. kENUP Foundation is grateful to President Kagame, President Sall and Prof. Dr. Şahin for their vision and courage, as well as to Africa CDC's Dr. John Nkengasong for his invaluable guidance. Many thanks to Team Europe, led by President von der Leyen and EIB President Hoyer, for their continuous engagement and meaningful support."
Producing COVID-19 vaccines in Africa came one step closer today after Team Europe formally agreed to support large-scale investment in vaccine production by the Institut Pasteur in Dakar, alongside other support measures. The new manufacturing plant should reduce Africa’s 99% dependence on vaccine imports and strengthen future pandemic resilience on the continent.
Backed by the eradicateMalaria initiative, German biotech company BioNTech SE (“BioNTech”) announced a project to develop a malaria vaccine candidate based on its proprietary mRNA technology today. The project also aims to expand vaccine production capacity across Africa. BioNTech co-developed the first mRNA-based COVID-19 vaccine with its partner Pfizer. The company has benefited from two European Investment Bank (EIB) loans under the Investment Plan for Europe for its cancer and COVID-19 research.
The EIB and BioNTech SE (Nasdaq: BNTX, BioNTech) today concluded a EUR 100 million debt financing agreement to support the development of BNT162, the company’s COVID-19 vaccine program. The deal will also allow the company to expand its manufacturing capacity in order to supply the vaccine fast worldwide in response to the pandemic. This will be done at the company’s own risk while the clinical studies are ongoing. BioNTech became the first European company to enter clinical testing, having started a clinical trial in Germany in April and a further clinical trial in the United States at the beginning of May. BioNTech’s development program for BNT162 is one of the broadest development programs globally, with four vaccine candidates being tested in parallel.